Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
Piccart, M J
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jun 2001 - 3103-10 p. digital
Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
0732-183X
10.1200/JCO.2001.19.12.3103 doi
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Belgium--epidemiology
Breast Neoplasms--drug therapy
Chemotherapy, Adjuvant--methods
Cyclophosphamide--administration & dosage
Disease-Free Survival
Dose-Response Relationship, Drug
Epirubicin--administration & dosage
Female
Fluorouracil--administration & dosage
Humans
Methotrexate--administration & dosage
Middle Aged
Prognosis
Proportional Hazards Models
Statistics, Nonparametric
Survival Rate
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jun 2001 - 3103-10 p. digital
Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
0732-183X
10.1200/JCO.2001.19.12.3103 doi
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Belgium--epidemiology
Breast Neoplasms--drug therapy
Chemotherapy, Adjuvant--methods
Cyclophosphamide--administration & dosage
Disease-Free Survival
Dose-Response Relationship, Drug
Epirubicin--administration & dosage
Female
Fluorouracil--administration & dosage
Humans
Methotrexate--administration & dosage
Middle Aged
Prognosis
Proportional Hazards Models
Statistics, Nonparametric
Survival Rate